<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2018-2-63-67</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-887</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Pre-stroke cognitive impairment and its impact on medication adherence</article-title><trans-title-group xml:lang="ru"><trans-title>Предшествующие инсульту когнитивные нарушения и их влияние на приверженность терапии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коваленко</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovalenko</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Контакты: Екатерина Андреевна Коваленко </p><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Contact: Ekaterina Andreevna Kovalenko </p><p>1, Ostrovityanov St., Moscow 117997</p></bio><email xlink:type="simple">ekaterinakov90@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Боголепова</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogolepova</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2018</year></pub-date><volume>10</volume><issue>2</issue><fpage>63</fpage><lpage>67</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kovalenko E.A., Bogolepova A.N., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Коваленко Е.А., Боголепова А.Н.</copyright-holder><copyright-holder xml:lang="en">Kovalenko E.A., Bogolepova A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/887">https://nnp.ima-press.net/nnp/article/view/887</self-uri><abstract><p>Adherence to long-term medication is one of the most important components of effective therapy. Many factors have a substantial influence on medication adherence; a special role among them is played by cognitive impairment (CI). </p><sec><title>Objective</title><p>Objective: to identify whether poststroke patients have pre-stroke cognitive deficit and to assess its impact on adherence to long-term medication. </p></sec><sec><title>Patients and methods</title><p>Patients and methods. A total of 103 patients with acute ischemic stroke in the carotid system were examined. The mean age of the patients was 64.18±10.24 years. The Montreal Cognitive Assessment (MoCA) was applied to assess cognitive functions; the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) was used to determine the presence of pre-stroke cognitive decline. Data concerning vascular risk factors were collected for all the patients. Medication adherence was retrospectively evaluated using the Morisky–Green scale. </p></sec><sec><title>Results and discussion</title><p>Results and discussion. Our study showed that only 44.7% of patients were adherent to long-term medication before the stroke. Patients who were engaged in manual labor during their lives were significantly more poorly compliant. Chronic heart failure was also responsible for a reduction in medication adherence. Pre-stroke cognitive deficit was present in 53.4% of the examinees. Unlike patients with normal cognitive function, the majority of patients with pre-stroke CI were non-adherent to medication (28.1 and 71.9%, respectively). At the same time, the adherence to long-term medication depended on the severity of cognitive deficit. </p></sec><sec><title>Conclusion</title><p>Conclusion. The results of the investigation suggest that CI has a considerable impact on adherence to long-term therapy. To improve primary stroke prevention, cognitive functions should be evaluated in all patients with vascular diseases who receive long-term drug treatment. When CI is identified, there is a need for targeted drug treatment and its proper monitoring. </p></sec></abstract><trans-abstract xml:lang="ru"><p>Приверженность длительной терапии – один из наиболее важных компонентов эффективной терапии. Многие факторы оказывают существенное влияние на приверженность терапии, особую роль среди них играют когнитивные нарушения (КН). </p><p>Цель исследования – определить у пациентов, перенесших инсульт, наличие доинсультного когнитивного дефицита и его влияние на приверженность длительной терапии. </p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Обследовано 103 пациента в остром периоде ишемического инсульта в каротидной системе. Средний возраст больных составил 64,18±10,24 года. Когнитивные функции оценивали по Монреальской шкале оценки когнитивных функций (MoCA); наличие доинсультного когнитивного снижения – по опроснику IQCODE. У всех пациентов собраны данные анамнеза о наличии сосудистых факторов риска. Приверженность терапии оценивали ретроспективно с помощью шкалы Мориски–Грина. </p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Исследование показало, что только 44,7% пациентов были привержены длительному лечению до развития инсульта. Пациенты, занимавшиеся в течение жизни физическим трудом, достоверно хуже выполняли медицинские рекомендации. Также влияние на снижение приверженности терапии оказывало наличие хронической сердечной недостаточности. Доинсультный когнитивный дефицит имелся у 53,4% обследованных. В отличие от больных с нормальным когнитивным функционированием, у большинства пациентов с предшествующими инсульту КН наблюдалось нарушение приверженности лечению (28,1 и 71,9% соответственно). При этом приверженность длительной терапии зависела от степени тяжести когнитивного дефицита. </p></sec><sec><title>Заключение</title><p>Заключение. Результаты исследования свидетельствуют о том, что КН оказывают значительное влияние на приверженность длительной терапии. С целью повышения уровня первичной профилактики инсульта все больные с сосудистыми заболеваниями, получающие длительную лекарственную терапию, нуждаются в оценке когнитивных функций. При выявлении КН необходимы направленное медикаментозное лечение и надлежащий контроль за его проведением.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>инсульт</kwd><kwd>доинсультные когнитивные нарушения</kwd><kwd>факторы риска</kwd><kwd>приверженность терапии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>stroke</kwd><kwd>pre-stroke cognitive impairment</kwd><kwd>risk factors</kwd><kwd>medication adherence</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов ВА. Факторы риска и вторичная профилактика ишемического инсульта. Нервные болезни. 2007;(1):2-8.</mixed-citation><mixed-citation xml:lang="en">Parfenov VA. Risk factors and secondary prevention of ischemic stroke. Nervnye bolezni. 2007;(1):2-8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Laufs U, Rettig-Ewen V, Bö hm M.Strategies to improve drug adherence. Eur Heart J. 2011 Feb;32(3):264-8. doi: 10.1093/eurheartj/ehq297. Epub 2010 Aug 21.</mixed-citation><mixed-citation xml:lang="en">Laufs U, Rettig-Ewen V, Böhm M.Strategies to improve drug adherence. Eur Heart J. 2011 Feb;32(3):264-8. doi: 10.1093/eurheartj/ehq297. Epub 2010 Aug 21.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Белоусов ЮБ, Леонова МВ. Особенности применения лекарства в гериатрической практике. Фарматека. 2008;(8):13-9</mixed-citation><mixed-citation xml:lang="en">Belousov YuB, Leonova MV. Specificity of using drugs in geriatric practice. Farmateka. 2008;(8):13-9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sabate E. Adherence to long-term therapies: evidence for action. World Health Organization; 2003.</mixed-citation><mixed-citation xml:lang="en">Sabate E. Adherence to long-term therapies: evidence for action. World Health Organization; 2003.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: A call for action.Am Heart J. 2011 Sep;162(3):412-24. doi: 10.1016/j.ahj.2011.06.007.</mixed-citation><mixed-citation xml:lang="en">Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: A call for action.Am Heart J. 2011 Sep;162(3):412-24. doi: 10.1016/j.ahj.2011.06.007.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Song X, Sander SD, Varker H, at al. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2012 Aug 1;12(4):245-53. doi: 10.2165/11632540-000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Song X, Sander SD, Varker H, at al. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2012 Aug 1;12(4):245-53. doi: 10.2165/11632540-000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008 Feb 26;117(8):1028-36. doi: 10.1161/CIRCULATIONAHA.107.706820.</mixed-citation><mixed-citation xml:lang="en">Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008 Feb 26;117(8):1028-36. doi: 10.1161/CIRCULATIONAHA.107.706820.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">O'Carroll R, Dennis M, Johnston M, et al. Improving adherence to medication in stroke survivors (IAMSS): a randomised controlled trial: study protocol. BMC Neurol. 2010 Feb 24;10:15. doi: 10.1186/1471-2377-10-15.</mixed-citation><mixed-citation xml:lang="en">O'Carroll R, Dennis M, Johnston M, et al. Improving adherence to medication in stroke survivors (IAMSS): a randomised controlled trial: study protocol. BMC Neurol. 2010 Feb 24;10:15. doi: 10.1186/1471-2377-10-15.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Arlt S, Lindner R, Rö sler A, et al. Adherence to medication in patients with dementia. Drugs Aging. 2008;25(12):1033-47. doi: 10.2165/0002512-200825120-00005.</mixed-citation><mixed-citation xml:lang="en">Arlt S, Lindner R, Rö sler A, et al. Adherence to medication in patients with dementia. Drugs Aging. 2008;25(12):1033-47. doi: 10.2165/0002512-200825120-00005.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Семенова ОН, Наумова ЕА. Факторы, влияющие на приверженность к терапии: параметры ВОЗ и мнение пациентов кардиологического отделения. Бюллетень медицинских интернет-конференций. 2013; 3(3):507-11.</mixed-citation><mixed-citation xml:lang="en">Semenova ON, Naumova EA. Factors affecting adherence to therapy: WHO parameters and patients ' opinion of the cardiology department. Byulleten' meditsinskikh internet-konferentsii. 2013;3(3):507-11. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Henon H, Pasquier F, Durieu MD, et al. Preexisting dementia in stroke patients. Stroke. 1997 Dec;28(12):2429-36.</mixed-citation><mixed-citation xml:lang="en">Henon H, Pasquier F, Durieu MD, et al. Preexisting dementia in stroke patients. Stroke. 1997 Dec;28(12):2429-36.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Вахнина НВ, Никитина ЛЮ, Парфенов ВА и др. Постинсультные когнитивные нарушения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;108(S22):16-21.</mixed-citation><mixed-citation xml:lang="en">Vakhnina NV, Nikitina LYu, Parfenov VA, et al. Post-stroke cognitive impairments. Zhurnalnevrologii i psikhiatrii im. S.S. Korsakova. 2008; 108(S22):16-21. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов ВА. Дисциркуляторная энцефалопатия и сосудистые когнитивные расстройства. Москва: ИМА-ПРЕСС; 2017. 124 с.</mixed-citation><mixed-citation xml:lang="en">Parfenov VA. Distsirkulyatornaya entsefalopatiya i sosudistye kognitivnye rasstroistva [Dyscirculatory encephalopathy and vascular cognitive disorders]. Moscow: IMA-PRESS; 2017. 124 p.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Saletu B, Garg A, Shoeb A. Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders. Biomed Res Int. 2014;2014:610103. doi: 10.1155/2014/610103. Epub 2014 Aug 28.</mixed-citation><mixed-citation xml:lang="en">Saletu B, Garg A, Shoeb A. Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders. Biomed Res Int. 2014;2014:610103. doi: 10.1155/2014/610103. Epub 2014 Aug 28.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bes A, Orgogozo JM, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol. 1999 May;6(3):313-22.</mixed-citation><mixed-citation xml:lang="en">Bes A, Orgogozo JM, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol. 1999 May;6(3):313-22.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159. doi: 10.1002/14651858.CD003159</mixed-citation><mixed-citation xml:lang="en">Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;(4):CD003159. doi: 10.1002/14651858.CD003159</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fioravanti M, Nakashima T, Xu J, Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open. 2014 Jul 30;4(7):e005090. doi: 10.1136/bmjopen-2014-005090.</mixed-citation><mixed-citation xml:lang="en">Fioravanti M, Nakashima T, Xu J, Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline. BMJ Open. 2014 Jul 30;4(7):e005090. doi: 10.1136/bmjopen-2014-005090.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
